Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 356

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 356
---
 |     | $ | 372,288 |
| Research and development               |     |   | 1,837,952 |     |   | 237,808 |
| Total stock-based compensation expense |     | $ | 2,831,783 |     | $ | 610,096 |

**Note 12-Commitmentsand contingencies**

Lease Commitments- The Company leases facilities under non-cancelableoperating leases for the laboratory and offices in Tampa, Florida. The current lease expires in March 2026.

Future minimum lease payments under these leases are as follows:

| Year ending December 31, 2025 (6 months)   |     | $ |  86,823 |   |
| Year ending December 31, 2026              |     |   |  43,411 |   |
| Interest portion of right of use liability |     |   |  (5,265 | ) |
| Operating lease liabilities                |     | $ | 124,969 |   |

Total lease expense was approximately $ 85,000and $ 78,000for the six months ended June 30, 2025 and 2024, respectively.

Cash paid for amounts included in the measurement of lease liabilities was approximately $ 86,000and $ 74,000for the six months ended June 30, 2025 and 2024.

For the current lease, the weighted-average lease term is 0.75years and 1.75years and the weighted average discount rate is 10.0% and 10.0% as of June 30, 2025 and 2024

Employment Agreements- The Company maintains employment agreements with its Chief Executive Officer and Chief Financial Officer, each entered into in May 2023 by Legacy TuHURA, as amended and as subsequently assumed by the Company in connection with the closing of the Kintara Merger.

Future minimum payments under these employment agreements are as follows:

| Year ending December 31, 2025 (6 months) |     | $ |   437,000 |
| Year ending December 31, 2026            |     |   |   874,000 |
|                                          |     | $ | 1,311,000 |

Note 13-Subsequentevents Subsequent events -The Company has evaluated subsequent events through August 14, 2025 in connection with the preparation of these unaudited condensed consolidated financial statements, which is the